Trial Profile
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccines (Primary) ; Interleukin-2 (Primary) ; Pembrolizumab (Primary)
- Indications Mesothelioma
- Focus Adverse reactions; Pharmacodynamics
- Acronyms MESOVAX
- 25 Feb 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Jan 2022.
- 20 Apr 2020 Status changed from not yet recruiting to recruiting.
- 26 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Apr 2019.